Market Cap: $6.95M
XL
XTL Biopharmaceuticals Ltd.
XTLB
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $6.95M
Strategic Acquisition Enhances Biopharmaceutical Capabilities for Servier In a significant development within the biopharmaceutical industry, Day One Biopharmaceuticals announces its acquisition by Se…
Rakuten Medical Enhances Manufacturing Capabilities through Strategic Partnership with LOTTE Biologics In a significant development at the J.P. Morgan Healthcare Conference, Rakuten Medical, Inc. anno…
X.T.L. Biopharmaceuticals Advances in mRNA Therapeutics Development X.T.L. Biopharmaceuticals, a frontrunner in the mRNA therapeutics space, announces significant progress in its proprietary drug deve…
Innovative Approaches to Obesity Management: Insights from Caliway Biopharmaceuticals' Research Caliway Biopharmaceuticals recently unveils its promising preclinical research on CBL-514 at the 25th An…
SK Biopharmaceuticals Expands Radiopharmaceutical Portfolio with WT-7695 License Agreement SK Biopharmaceuticals, a South Korean biotech firm specializing in treatments for central nervous system (CNS…
Innovative Venture in Epilepsy Management: SK Biopharmaceuticals Partners with Eurofarma In a significant development for digital healthcare, SK Biopharmaceuticals, a company renowned for its advancem…
SK Biopharmaceuticals Expands into Digital Healthcare with AI-Driven Epilepsy Management Platform In a significant move to enhance its portfolio in the digital healthcare landscape, SK Biopharmaceutic…
Innovative CAR-T Therapy Partnership Aims to Transform Cancer Treatment in Singapore Elpis Biopharmaceuticals, a clinical-stage cell therapy company based in Lexington, Massachusetts, forges a strateg…
Elpis Biopharmaceuticals Partners with NCCS to Advance CAR-T Therapy for Solid Tumors Elpis Biopharmaceuticals, a clinical-stage cell therapy innovator, has entered a pivotal partnership with the Nati…
Hillhurst Biopharmaceuticals Advances Treatment for Sickle Cell Disease with Phase 2a Trial Hillhurst Biopharmaceuticals Inc. has marked a pivotal moment in its research efforts by initiating the dosi…
Strategic Merger Enhances Impact Biomedical's Growth Potential Impact Biomedical, Inc. (IBO) announces a strategic merger and share exchange agreement with Dr. Ashleys, marking a significant developme…
Strategic Partnerships: A Catalyst for Growth in Biopharmaceuticals Impact Biomedical, Inc. (IBO) underscores the importance of strategic partnerships in the rapidly evolving biopharmaceutical landsca…
Impact Biomedical’s Strategic Merger: A Step Towards Industry Leadership Impact Biomedical, Inc. (IBO) announces a significant merger and share exchange agreement with the esteemed Dr. Ashleys, a move…
Strategic Alliance in Biopharmaceutical Innovation Sanyou Biopharmaceuticals and Medicovestor, Inc. forge a significant strategic cooperation agreement aimed at revolutionizing the treatment landscape…
Innovative Collaboration: Sanyou Biopharmaceuticals Partners with Medicovestor to Advance Chemoimmunotherapy In a transformative move for the biopharmaceutical landscape, Sanyou Biopharmaceuticals has…
Elpis Biopharmaceuticals Advances Cancer Treatment Through Strategic Collaboration Elpis Biopharmaceuticals, a clinical-stage company specializing in innovative cell therapies, has recently solidified…
Elpis Biopharmaceuticals Partners with Singapore General Hospital for Advanced Cancer Therapies Elpis Biopharmaceuticals, a pioneering company in the field of cell therapy, announces a strategic resea…
Elpis Biopharmaceuticals and Singapore General Hospital Forge Strategic Collaboration in CAR-T Therapy Development In a significant advancement in cancer treatment, Elpis Biopharmaceuticals has partne…
Elpis Biopharmaceuticals Advances Bispecific Armored CAR-T Therapies for Solid Tumors Elpis Biopharmaceuticals, a clinical-stage company focused on cell therapy, is leading the way in the development…
Elpis Biopharmaceuticals Advances Bispecific Armored CAR-T Therapy for Solid Tumors Elpis Biopharmaceuticals is at the forefront of innovation in the field of cell therapies, particularly with its dev…
Elpis Biopharmaceuticals Unveils Breakthrough in CAR-T Therapy for Solid Tumors Elpis Biopharmaceuticals, a clinical-stage cell therapy company, is poised to revolutionize the treatment of solid tumor…
Kangpu Biopharmaceuticals Advances Treatment for Systemic Lupus Erythematosus Kangpu Biopharmaceuticals, Ltd. makes significant strides in the fight against systemic lupus erythematosus (SLE) with the…
Kangpu Biopharmaceuticals Expands Clinical Development with KPG-818 for Systemic Lupus Erythematosus Kangpu Biopharmaceuticals, Ltd. recently receives approval from the Center for Drug Evaluation (CDE…
Strategic Partnership to Streamline Biopharmaceutical Development In a significant move for the biopharmaceutical industry, ERBC, a leading preclinical contract research organization, teams up with Me…
Strategic Collaboration to Propel Biopharmaceutical Innovations In a significant move for the biopharmaceutical industry, ERBC and Menarini Biotech announce a strategic partnership aimed at streamlini…
Streamlining Biopharmaceutical Development: A New Era for Early-Stage Innovations In a significant development for the biopharmaceutical sector, ERBC, a leading preclinical contract research organizat…
Advancing Gene Therapy Manufacturing: A Significant Collaboration in Biopharmaceuticals X.T.L. Biopharmaceuticals Ltd. stands at the forefront of an evolving landscape in gene therapy manufacturing, p…
Innovations in Lipid Nanoparticle Technology: A New Frontier in RNA Delivery HighField Biopharmaceuticals, a pioneering clinical-stage company based in Hangzhou, China, is making significant strides i…
HighField Biopharmaceuticals Pioneers Innovative Cancer Therapy with IND Clearance for HF50 HighField Biopharmaceuticals, a clinical-stage biotechnology firm based in Hangzhou, China, is poised to mak…
SK Biopharmaceuticals Partners with ProEn Therapeutics to Advance Radiopharmaceutical Development SK Biopharmaceuticals, a prominent player in the biopharmaceutical landscape, has recently announced a…
Caliway Biopharmaceuticals Strengthens Its Position in the Biotech Landscape Caliway Biopharmaceuticals Co., Ltd. announces its inclusion in two prestigious indices, the FTSE TWSE Taiwan Mid-Cap 100 I…
Atlas Venture's New Fund: A Catalyst for Biotech Innovation Atlas Venture, a leading early-stage venture capital firm based in Cambridge, Massachusetts, has successfully closed its fourteenth fund, ra…
X.T.L. Biopharmaceuticals Ltd. Strengthens Its Position in Radiopharmaceutical Development X.T.L. Biopharmaceuticals Ltd. stands at a pivotal moment in the evolving landscape of cancer therapies, part…